Abbott Labs: Deep Value Thesis Meets Integration and Litigation Hurdles

What happened

A Seeking Alpha article argues Abbott Laboratories is structurally undervalued, trading at a 17.1% P/E and 35.1% sales multiple discount to peers, with DCF fair value estimates implying 21.8–39.4% upside. However, the latest DeepValue master report rates ABT a WAIT, citing exacting risks from the Exact Sciences acquisition, an FDA warning letter and Class I recall on Libre 3 sensors, and NEC infant-formula litigation with a potential $70M jury award. Near-term catalysts include 2Q26 results—the first full quarter with Exact—and the August 2026 bellwether trial window, which could escalate legal overhang. While Devices momentum (Libre CGM +7.6%) and a strong balance sheet provide a buffer, integration costs have already pushed SG&A up $679M in 1Q26. The stock's return profile depends on whether Abbott can prove Diagnostics acceleration, contain dilution within FY26 EPS guidance of $5.38–$5.58, and avoid a string of adverse verdicts.

Implication

Investors should remain cautious until Abbott demonstrates that Exact Sciences integration lifts Diagnostics growth above low-single-digits and that NEC verdicts remain manageable. The Seeking Alpha strong buy thesis may prove correct if Abbott delivers on these fronts, but the current risk/reward favors avoiding the stock until the 2Q26 earnings and August bellwether outcomes reduce uncertainty. A disciplined entry near $82 (the report's attractive entry) would offer a better margin of safety if thesis breakers are avoided.

Thesis delta

The Seeking Alpha article's bullish structural undervaluation argument is a necessary condition but not sufficient: DeepValue analysis reveals that near-term risks from integration, FDA compliance, and litigation could delay or derail value realization. The strong buy narrative is premature; the correct posture is to wait for confirmatory signals that the positive thesis breakers (sustained Devices growth, Diagnostics inflection, steady guidance) are intact and the negative ones (additional large NEC verdicts, FDA escalation) are contained.